Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Coronary Atherosclerosis in T2DM (T-PLAQUE)
NCT05708859Phase 4Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in atherosclerosis and type 2 diabetes mellitus (T2DM) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Reduction of total non-calcified coronary plaque volume at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
atherosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05708859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05708859.